Jeil Pharmaceutical Co.,Ltd (271980.KS)
KRW 11640.0
(-5.6%)
KRW 11640.0
(-5.6%)
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2023 | 109.76 Billion KRW | 10.71% |
| 2022 | 99.15 Billion KRW | -3.23% |
| 2021 | 102.45 Billion KRW | -6.27% |
| 2020 | 109.31 Billion KRW | 30.02% |
| 2019 | 84.07 Billion KRW | -4.95% |
| 2018 | 88.44 Billion KRW | 5.68% |
| 2017 | 83.69 Billion KRW | 4.03% |
| 2016 | 80.45 Billion KRW | 9.28% |
| 2015 | 73.62 Billion KRW | 0.0% |
| Year | Inventory | Inventory Growth |
|---|---|---|
| 2024 Q1 | 115.89 Billion KRW | 5.58% |
| 2024 Q2 | 118.79 Billion KRW | 2.5% |
| 2023 Q1 | 116.04 Billion KRW | 17.03% |
| 2023 FY | 109.76 Billion KRW | 10.71% |
| 2023 Q4 | 109.76 Billion KRW | -12.87% |
| 2023 Q3 | 125.98 Billion KRW | 8.87% |
| 2023 Q2 | 115.72 Billion KRW | -0.28% |
| 2022 FY | 99.15 Billion KRW | -3.23% |
| 2022 Q2 | 100.53 Billion KRW | 3.43% |
| 2022 Q1 | 97.2 Billion KRW | -5.13% |
| 2022 Q4 | 99.15 Billion KRW | -2.05% |
| 2022 Q3 | 101.22 Billion KRW | 0.68% |
| 2021 FY | 102.45 Billion KRW | -6.27% |
| 2021 Q2 | 107.65 Billion KRW | -0.86% |
| 2021 Q1 | 108.59 Billion KRW | -0.66% |
| 2021 Q3 | 102.74 Billion KRW | -4.56% |
| 2021 Q4 | 102.45 Billion KRW | -0.28% |
| 2020 FY | 109.31 Billion KRW | 30.02% |
| 2020 Q1 | 97.76 Billion KRW | 16.29% |
| 2020 Q4 | 109.31 Billion KRW | -4.3% |
| 2020 Q3 | 114.22 Billion KRW | 7.59% |
| 2020 Q2 | 106.16 Billion KRW | 8.59% |
| 2019 Q1 | 91.71 Billion KRW | 3.7% |
| 2019 Q4 | 84.07 Billion KRW | 4.99% |
| 2019 FY | 84.07 Billion KRW | -4.95% |
| 2019 Q3 | 80.07 Billion KRW | -3.28% |
| 2019 Q2 | 82.79 Billion KRW | -9.73% |
| 2018 FY | 88.44 Billion KRW | 5.68% |
| 2018 Q4 | 88.44 Billion KRW | 3.63% |
| 2018 Q3 | 85.34 Billion KRW | 7.68% |
| 2018 Q2 | 79.26 Billion KRW | -0.89% |
| 2018 Q1 | 79.97 Billion KRW | -4.44% |
| 2017 Q3 | 87.77 Billion KRW | 6.62% |
| 2017 Q4 | 83.69 Billion KRW | -4.65% |
| 2017 FY | 83.69 Billion KRW | 4.03% |
| 2017 Q2 | 82.32 Billion KRW | 0.0% |
| 2016 FY | 80.45 Billion KRW | 9.28% |
| 2015 FY | 73.62 Billion KRW | 0.0% |
| Name | Inventory | Inventory Difference |
|---|---|---|
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -148.613% |
| Dong-A Socio Holdings Co., Ltd. | 117.85 Billion KRW | 6.86% |
| Ildong Holdings Co., Ltd. | 91.16 Billion KRW | -20.404% |
| HANDOK Inc. | 94.46 Billion KRW | -16.2% |
| Kukje Pharma Co., Ltd. | 21.24 Billion KRW | -416.723% |
| Yuhan Corporation | 284.75 Billion KRW | 61.452% |
| Dong-A ST Co., Ltd. | 116.31 Billion KRW | 5.627% |
| SAMSUNG PHARM. Co., LTD. | 16.25 Billion KRW | -575.135% |
| Hanmi Pharm. Co., Ltd. | 288.81 Billion KRW | 61.993% |
| Hanall Biopharma Co.,Ltd | 32.38 Billion KRW | -238.956% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -77.835% |
| Dong Sung Bio Pharm.Co.,Ltd. | 19.47 Billion KRW | -463.576% |
| MYUNGMOON Pharm co.,Ltd | 30.28 Billion KRW | -262.507% |
| Hana Pharm Co., Ltd. | 48.34 Billion KRW | -127.041% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -148.613% |
| Ilsung Pharmaceuticals Co., Ltd. | 31.24 Billion KRW | -251.361% |
| REYON Pharmaceutical Co., Ltd. | 35.17 Billion KRW | -212.05% |
| Aprogen pharmaceuticals,Inc. | 48.12 Billion KRW | -128.074% |
| JW Holdings Corporation | 147.58 Billion KRW | 25.626% |
| Ildong Pharmaceutical Co., Ltd. | 84.62 Billion KRW | -29.713% |
| Chong Kun Dang Pharmaceutical Corp. | 261.43 Billion KRW | 58.013% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -3.466% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -103.563% |
| Hyundai Pharmaceutical Co., Ltd. | 26.99 Billion KRW | -306.579% |
| Samil Pharmaceutical Co.,Ltd | 32.51 Billion KRW | -237.629% |
| Yuyu Pharma, Inc. | 44.15 Billion KRW | -148.613% |
| Kwang Dong Pharmaceutical Co., Ltd. | 188.64 Billion KRW | 41.812% |
| Daewoong pharmaceutical Co.,Ltd | 241.54 Billion KRW | 54.556% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -3.466% |
| Yuhan Corporation | 284.75 Billion KRW | 61.452% |
| Jeil Pharma Holdings Inc | 125.28 Billion KRW | 12.382% |
| Yungjin Pharm. Co., Ltd. | 61.98 Billion KRW | -77.083% |
| Suheung Co., Ltd. | 259.84 Billion KRW | 57.756% |
| JW Pharmaceutical Corporation | 106.09 Billion KRW | -3.466% |
| Samjin Pharmaceuticals Co., Ltd. | 79.6 Billion KRW | -37.895% |
| Korea United Pharm Inc. | 49.14 Billion KRW | -123.369% |
| CKD Bio Corp. | 69.08 Billion KRW | -58.895% |
| Daewon Pharmaceutical Co., Ltd. | 105.07 Billion KRW | -4.463% |
| Dongwha Pharm.Co.,Ltd | 70.69 Billion KRW | -55.265% |
| Whan In Pharm Co.,Ltd. | 54.05 Billion KRW | -103.056% |
| Shin Poong Pharm.Co.,Ltd. | 53.92 Billion KRW | -103.563% |
| Chong Kun Dang Holdings Corp. | 194.76 Billion KRW | 43.641% |
| Boryung Corporation | 189.8 Billion KRW | 42.168% |
| Bukwang Pharmaceutical Co., Ltd. | 56.83 Billion KRW | -93.145% |
| Ilyang Pharmaceutical Co.,Ltd | 61.72 Billion KRW | -77.835% |
| JW Lifescience Corporation | 23.39 Billion KRW | -369.122% |